{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:02Z","timestamp":1792782662825,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22306015"],"award-info":[{"award-number":["22306015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22376016"],"award-info":[{"award-number":["22376016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22022601"],"award-info":[{"award-number":["22022601"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science Innovation 2030-Brain Science and Brain-Inspired Intelligence Technology Major Projects","award":["2021ZD0201103"],"award-info":[{"award-number":["2021ZD0201103"]}]},{"name":"Science Innovation 2030-Brain Science and Brain-Inspired Intelligence Technology Major Projects","award":["2021ZD0201803"],"award-info":[{"award-number":["2021ZD0201803"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-025-07719-9","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T06:09:55Z","timestamp":1768025395000},"page":"3364-3374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical and preliminary clinical evaluation of [18F]Florbetazine for non-invasive PET detection of cardiac amyloidosis"],"prefix":"10.1007","volume":"53","author":[{"given":"Yuying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-xin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-7864","authenticated-orcid":false,"given":"Mengchao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"10038","key":"7719_CR1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641\u201354.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"7719_CR2","doi-asserted-by":"publisher","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","volume":"18","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med. 2018;18(Suppl 2):s30\u20135.","journal-title":"Clin Med"},{"issue":"3","key":"7719_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","volume":"94","author":"RA Kyle","year":"2019","unstructured":"Kyle RA, Larson DR, Kurtin PJ, et al. Incidence of AL amyloidosis in Olmsted county, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465\u201371.","journal-title":"Mayo Clin Proc"},{"key":"7719_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106761","volume":"194","author":"RH Eggleston","year":"2022","unstructured":"Eggleston RH, Hartman TE, Walkoff LA, Yi ES, Ryu JH, Baqir M. Clinical, radiologic, and pathologic features and outcomes of pulmonary transthyretin amyloidosis. Respir Med. 2022;194:106761.","journal-title":"Respir Med"},{"issue":"13","key":"7719_CR5","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047\u201360.","journal-title":"Circulation"},{"issue":"2","key":"7719_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coph.2005.10.005","volume":"6","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6(2):214\u201320.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"7719_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):39.","journal-title":"Nat Rev Dis Primers"},{"issue":"13","key":"7719_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203\u201312.","journal-title":"Circulation"},{"issue":"15","key":"7719_CR9","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111\u20139.","journal-title":"Blood"},{"issue":"12","key":"7719_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"7719_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"7719_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","volume":"70","author":"A Martinez-Naharro","year":"2017","unstructured":"Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466\u201377.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"7719_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail. 2021;23(4):512\u201326.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"7719_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2967\/jnumed.120.245381","volume":"61","author":"A Masri","year":"2020","unstructured":"Masri A, Bukhari S, Eisele YS, Soman P. Molecular imaging of cardiac amyloidosis. J Nucl Med. 2020;61(7):965\u201370.","journal-title":"J Nucl Med"},{"issue":"1","key":"7719_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s11886-024-02114-6","volume":"26","author":"AJ Romero Pabon","year":"2024","unstructured":"Romero Pabon AJ, Clerc OF, Vijayakumar S, Cuddy SaM, Dorbala S. Recent advances in positron emission tomography radiotracers to image cardiac amyloidosis. Curr Cardiol Rep. 2024;26(1):1153\u201362.","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"7719_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s11886-011-0239-5","volume":"14","author":"W Chen","year":"2012","unstructured":"Chen W, Dilsizian V. Molecular imaging of amyloidosis: will the heart be the next target after the brain? Curr Cardiol Rep. 2012;14(2):226\u201333.","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"7719_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11886-017-0868-4","volume":"19","author":"PE Bravo","year":"2017","unstructured":"Bravo PE, Dorbala S. Targeted nuclear imaging probes for cardiac amyloidosis. Curr Cardiol Rep. 2017;19(7):59.","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"7719_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11936-020-00890-2","volume":"23","author":"D Toy","year":"2021","unstructured":"Toy D, Groner LK, Escalon JG, et al. Updates on the role of imaging in cardiac amyloidosis. Curr Treat Options Cardiovasc Med. 2021;23(2):11.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"1","key":"7719_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","volume":"26","author":"V Singh","year":"2019","unstructured":"Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019;26(1):158\u201373.","journal-title":"J Nucl Cardiol"},{"issue":"24","key":"7719_CR20","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","volume":"44","author":"MU Rauf","year":"2023","unstructured":"Rauf MU, Hawkins PN, Cappelli F, et al. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J. 2023;44(24):2187\u201398.","journal-title":"Eur Heart J"},{"issue":"2","key":"7719_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Casta\u00f1o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circulation-cardiovas Imag. 2013;6(2):195\u2013201.","journal-title":"Circulation-cardiovas Imag"},{"issue":"4","key":"7719_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s12350-015-0287-0","volume":"23","author":"A Van Der Gucht","year":"2016","unstructured":"Van Der Gucht A, Galat A, Rosso J, et al. [18F]-NaF PET\/CT imaging in cardiac amyloidosis. J Nucl Cardiol. 2016;23(4):846\u20139.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"7719_CR23","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s12350-016-0457-8","volume":"24","author":"C Gagliardi","year":"2017","unstructured":"Gagliardi C, Tabacchi E, Bonfiglioli R, et al. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET\/CT? J Nucl Cardiol. 2017;24(2):746\u20139.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"7719_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","volume":"27","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Ha S, Kim YI. Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis. J Nucl Cardiol. 2020;27(1):123\u201332.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"7719_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","volume":"75","author":"SP Lee","year":"2020","unstructured":"Lee SP, Suh HY, Park S, et al. Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis. J Am Coll Cardiol. 2020;75(4):380\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"7719_CR26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.2967\/jnumed.121.263033","volume":"63","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Koh Y, Lee HJ, et al. Independent prognostic utility of 11C-Pittsburgh compound B PET in patients with light-chain cardiac amyloidosis. J Nucl Med. 2022;63(7):1064\u20139.","journal-title":"J Nucl Med"},{"issue":"6","key":"7719_CR27","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s12350-017-0856-5","volume":"24","author":"D Genovesi","year":"2017","unstructured":"Genovesi D, Vergaro G, Emdin M, Giorgetti A, Marzullo P. PET-CT evaluation of amyloid systemic involvement with [18F]-florbetaben in patient with proved cardiac amyloidosis: a case report. J Nucl Cardiol. 2017;24(6):2025\u20139.","journal-title":"J Nucl Cardiol"},{"key":"7719_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.693194","volume":"8","author":"BW Sperry","year":"2021","unstructured":"Sperry BW, Bock A, Difilippo FP, Donnelly JP, Hanna M, Jaber WA. Pilot study of F18-florbetapir in the early evaluation of cardiac amyloidosis. Front Cardiovasc Med. 2021;8:693194.","journal-title":"Front Cardiovasc Med"},{"key":"7719_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.830572","volume":"9","author":"X Bi","year":"2022","unstructured":"Bi X, Xu B, Liu J, et al. Diagnostic value of 11C-PIB PET\/MR in cardiac amyloidosis. Front Cardiovasc Med. 2022;9:830572.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"7719_CR30","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00259-018-3995-2","volume":"45","author":"T Wagner","year":"2018","unstructured":"Wagner T, Page J, Burniston M, et al. Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds. Eur J Nucl Med Mol Imaging. 2018;45(7):1129\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"7719_CR31","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","volume":"46","author":"M Kircher","year":"2019","unstructured":"Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with 18F-florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46(7):1407\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7719_CR32","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00259-019-04627-7","volume":"47","author":"YM Khor","year":"2019","unstructured":"Khor YM, Cuddy S, Harms HJ, et al. Quantitative [18F]florbetapir PET\/CT may identify lung involvement in patients with systemic AL amyloidosis. Eur J Nucl Med Mol Imaging. 2019;47(8):1998\u20132009.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7719_CR33","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/RLU.0000000000004411","volume":"47","author":"EJ Han","year":"2022","unstructured":"Han EJ, Sung YE, Jung MH, O JH, Youn JC. 18F-flutemetamol PET\/CT for transthyretin amyloid cardiomyopathy: timing matters. Clin Nucl Med. 2022;47(12):1074\u20136.","journal-title":"Clin Nucl Med"},{"key":"7719_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.114.002954","author":"MA Park","year":"2015","unstructured":"Park MA, Padera RF, Belanger A, et al. 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ Cardiovasc Imaging. 2015. https:\/\/doi.org\/10.1161\/CIRCIMAGING.114.002954.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"7719_CR35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","volume":"14","author":"D Genovesi","year":"2021","unstructured":"Genovesi D, Vergaro G, Giorgetti A, et al. [18F]-florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imaging. 2021;14(1):246\u201355.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"7719_CR36","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7719_CR37","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.3390\/molecules20057657","volume":"20","author":"JS Wall","year":"2015","unstructured":"Wall JS, Martin EB, Richey T, et al. Preclinical validation of the heparin-reactive peptide p5+14 as a molecular imaging agent for visceral amyloidosis. Molecules. 2015;20(5):7657\u201382.","journal-title":"Molecules"},{"issue":"11","key":"7719_CR38","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","volume":"16","author":"JS Wall","year":"2023","unstructured":"Wall JS, Martin EB, Lands R, et al. Cardiac amyloid detection by PET\/CT imaging of iodine (124I) Evuzamitide (124I\u2013p5+14): a phase 1\/2 study. JACC-Cardiovasc Imag. 2023;16(11):1433\u201348.","journal-title":"JACC-Cardiovasc Imag"},{"key":"7719_CR39","doi-asserted-by":"crossref","unstructured":"Clerc OF, Cuddy SaM, Robertson M, et al., Cardiac amyloid quantification using 124I-Evuzamitide (124I-P5+14) versus 18F-Florbetapir: a pilot PET\/CT study. JACC-Cardiovasc Imag. 2023;16(11):1419\u20131432.","DOI":"10.1016\/j.jcmg.2023.07.007"},{"issue":"7","key":"7719_CR40","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1021\/acs.jmedchem.2c01503","volume":"66","author":"YY Li","year":"2023","unstructured":"Li YY, Zhou KX, Zhang XJ, et al. Fluorine-18-labeled diaryl-azines as improved \u03b2-amyloid imaging tracers: from bench to first-in-human studies. J Med Chem. 2023;66(7):4603\u201316.","journal-title":"J Med Chem"},{"issue":"14","key":"7719_CR41","doi-asserted-by":"publisher","first-page":"15198","DOI":"10.1021\/acs.jmedchem.5c01485","volume":"68","author":"Q Wang","year":"2025","unstructured":"Wang Q, Song JN, Zhang XJ, et al. Rational design of pyridinium styryl derivatives as PET tracers for cardiac amyloidosis imaging. J Med Chem. 2025;68(14):15198\u2013212.","journal-title":"J Med Chem"},{"issue":"14","key":"7719_CR42","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1021\/acs.jmedchem.3c00239","volume":"66","author":"TQ Liu","year":"2023","unstructured":"Liu TQ, Li YY, Zhang XJ, et al. Synthesis and preclinical evaluation of 2-(4-[18F]fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([18F]FPND-4): an aza-fused tricyclic derivative as positron emission tomography tracer for neurofibrillary tangle imaging. J Med Chem. 2023;66(14):9561\u201376.","journal-title":"J Med Chem"},{"issue":"1","key":"7719_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","volume":"109","author":"K Tagai","year":"2021","unstructured":"Tagai K, Ono M, Kubota M, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and Non-Alzheimer\u2019s disease tauopathies. Neuron. 2021;109(1):42-58.e48.","journal-title":"Neuron"},{"key":"7719_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202502450","author":"AY Sun","year":"2025","unstructured":"Sun AY, Lv GL, Li KD, et al. A 2-methyl-butadiene based probe for enhancing photostability and tau pathology detection. Adv Healthc Mater. 2025. https:\/\/doi.org\/10.1002\/adhm.202502450.","journal-title":"Adv Healthc Mater"},{"issue":"10","key":"7719_CR45","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","volume":"59","author":"AM Walji","year":"2016","unstructured":"Walji AM, Hostetler ED, Selnick H, et al. Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59(10):4778\u201389.","journal-title":"J Med Chem"},{"issue":"1","key":"7719_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/13506129.2013.860895","volume":"21","author":"E Hellstr\u00f6m-Lindahl","year":"2013","unstructured":"Hellstr\u00f6m-Lindahl E, Westermark P, Antoni G, Estrada S. In vitrobinding of [3H]PIB to human amyloid deposits of different types. Amyloid. 2013;21(1):21\u20137.","journal-title":"Amyloid"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07719-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:01:38Z","timestamp":1774404098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07719-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7719"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07719-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures complied with institutional and national guidelines and were approved by the Animal Care and Use Committee of Beijing Normal University (BNUCC-EAW-2023-0615-01). Healthy volunteers were enrolled in a phase I clinical trial of [\n                      18\n                      F]Florbetazine conducted in China, All PET\/CT imaging procedures were performed in accordance with the principles approved by the ethics committee of the Chinese PLA General Hospital. The trial is registered at ClinicalTrials.gov (NCT06593626). A patient with biopsy-confirmed amyloidosis underwent [\n                      18\n                      F]Florbetazine PET\/CT imaging under a protocol approved by the Clinical Research Ethics Committee of the General Hospital of Tianjin Medical University, and the trail is registered at ClinicalTrials.gov (NCT06725706).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All reported subjects provided written informed consent to participate in the clinical study and for the publication of their anonymized case details and medical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing financial interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}